S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Fund/Baker Bros Advisors/Q4 2020

Baker Bros Advisors

Periodo: Q4 2020 Β· Depositato: 2021-02-16
Vedi su SEC EDGAR β†—
AUM
$26.54B
Valore totale del portafoglio
Posizioni
126
Titoli dichiarati
Prima Posizione
SGEN
31.2% $8.28B
Var. Trimestrali
+8 / -8
nuovi Β· usciti
⚠️Informativa sui Depositi 13F

I dati AUM mostrati sono calcolati sommando il valore di mercato dichiarato di tutte le posizioni nei depositi SEC 13F-HR β€” non rappresentano il patrimonio effettivo gestito dal fondo.

  • Escluse liquiditΓ , obbligazioni, private equity, posizioni corte e azioni estere non soggette all'obbligo di dichiarazione.
  • Per le opzioni PUT e CALL, il Valore dichiarato Γ¨ il valore nozionale delle azioni sottostanti β€” non il premio pagato. CiΓ² sovrastima significativamente il capitale effettivamente a rischio.
  • Il patrimonio reale del fondo Γ¨ tipicamente superiore e include strategie, strumenti e posizioni che non compaiono mai in un 13F.
  • I depositi 13F riguardano i gestori istituzionali con β‰₯$100M in titoli 13F. Le posizioni riflettono le partecipazioni a fine trimestre, divulgate entro 45 giorni dalla fine del periodo.

Dati provenienti da SEC EDGAR. Questo tracker Γ¨ a scopo puramente informativo e non costituisce consulenza finanziaria.

Partecipazioni in Portafoglio

Prime 30 posizioni

⚠️ Performance % calcolata dalla data di deposito ( 2021-02-16) si riferisce al titolo sottostante β€” non al P&L del derivato.
TickerEmittenteNozionalePortafoglio %Al DepositoOra (Fine Giornata)Dal DepositoAllocazione
SGENSeagen Inc.$8.28B31.19%β€”β€”
31.2%
ONCBeiGene, Ltd.$3.02B11.36%$258.39$297.65+15.2%
11.4%
INCYIncyte Corporation$2.78B10.49%$86.98$116.86+34.4%
10.5%
ACADACADIA Pharmaceuticals Inc.$2.24B8.44%$53.46$25.97-51.4%
8.4%
KODKodiak Sciences Inc.$2.04B7.68%$146.91$38.54-73.8%
7.7%
ALXNAlexion Pharmaceuticals, Inc.$1.37B5.16%β€”β€”
5.2%
PRLDPrelude Therapeutics Incorporated$724.0M2.73%$71.55$4.91-93.1%
2.7%
BMRNBioMarin Pharmaceutical Inc.$665.5M2.51%$87.69$58.99-32.7%
2.5%
NVTAQInvitae Corporation$654.3M2.46%β€”β€”
2.5%
ASNDAscendis Pharma A/S$590.5M2.22%$166.78$274.50+64.6%
2.2%
ABCLAbCellera Biologics Inc.$420.5M1.58%$40.24$8.11-79.8%
1.6%
MRTXMirati Therapeutics, Inc.$309.6M1.17%β€”β€”
1.2%
ARGXargenx SE$299.8M1.13%$294.09$939.68+219.5%
1.1%
IGMSIGM Biosciences, Inc.$277.7M1.05%β€”β€”
1.1%
MDGLMadrigal Pharmaceuticals, Inc.$166.7M0.63%$111.17$528.10+375.0%
0.6%
AMRNXXXXAmarin Corporation plc$136.9M0.52%β€”β€”
0.5%
HRTXHeron Therapeutics, Inc.$126.9M0.48%$21.17$0.44-97.9%
0.5%
KYMRKymera Therapeutics, Inc.$121.5M0.46%$62.00$113.51+83.1%
0.5%
ALLKAllakos Inc.$100.0M0.38%β€”β€”
0.4%
CERSCerus Corporation$94.9M0.36%$6.92$3.16-54.3%
0.4%
BCRXBioCryst Pharmaceuticals, Inc.$94.6M0.36%$7.45$9.84+32.1%
0.4%
PACBPacific Biosciences of California, Inc.$83.1M0.31%$25.94$1.68-93.5%
0.3%
ZYMEZymeworks Inc.$80.7M0.30%$47.26$26.31-44.3%
0.3%
INSMInsmed Incorporated$71.8M0.27%$33.29$111.60+235.2%
0.3%
FMTXForma Therapeutics Holdings, Inc.$70.7M0.27%β€”β€”
0.3%
RYTMRhythm Pharmaceuticals, Inc.$68.8M0.26%$29.73$114.17+284.0%
0.3%
NBIXNeurocrine Biosciences, Inc.$64.9M0.24%$95.85$174.26+81.8%
0.2%
AXSMAxsome Therapeutics, Inc.$63.5M0.24%$81.47$244.31+199.9%
0.2%
RAREUltragenyx Pharmaceutical Inc.$61.5M0.23%$138.43$33.47-75.8%
0.2%
NRIXNurix Therapeutics, Inc.$58.8M0.22%$32.88$23.97-27.1%
0.2%

AttivitΓ  Trimestre su Trimestre

Q4 2020 vs. Q3 2020

Nuove Posizioni (8)

TickerEmittenteNozionaleDal Deposito
ABCLAbCellera Biologics Inc.$420.5M-79.8%
RAREUltragenyx Pharmaceutical Inc.$61.5M-75.8%
ALGSAligos Therapeutics, Inc.$44.5M
OPTEYOpthea Limited$37.1M
BCABBioAtla, Inc.$28.1M
VSTMXXXXVerastem, Inc.$21.6M
MREOMereo BioPharma Group plc$21.6M
KDNYChinook Therapeutics, Inc.$11.9M

Posizioni Chiuse (8)

TickerEmittenteNozionale
MYOKMyoKardia, Inc.$410.3M
EXASExact Sciences Corporation$188.2M
Neurocrine Biosciences, Inc.$42.3M
IMMUImmunomedics, Inc.$20.2M
UROVUrovant Sciences Ltd.$9.1M
CPRXCatalyst Pharmaceuticals, Inc.$1.4M
APLTApplied Therapeutics, Inc.$0.8M
ARAVAravive, Inc.$0.4M

Aumentate (8)

TickerEmittenteNozionaleVar. Azioni
GTHGenetron Holdings Limited$5.2M+355.3%
RETAReata Pharmaceuticals, Inc.$22.5M+321.1%
GMDAQGamida Cell Ltd.$10.4M+144.5%
CRNXCrinetics Pharmaceuticals, Inc.$4.0M+103.9%
IMTXImmatics N.V.$8.8M+80.2%
AUTLAutolus Therapeutics plc$1.6M+69.6%
OVIDOvid Therapeutics Inc.$-1.2M+61.8%
ADAPYAdaptimmune Therapeutics plc$2.5M+55.3%

Ridotte (8)

TickerEmittenteNozionaleVar. Azioni
QUREuniQure N.V.$-6.9M-96.5%
KZRKezar Life Sciences, Inc.$-2.0M-75.7%
HRMYHarmony Biosciences Holdings, Inc.$-7.0M-55.0%
GNFTYGenfit SA$-0.1M-48.2%
RCUSArcus Biosciences, Inc.$-0.1M-37.0%
CCXIChemoCentryx, Inc.$-8.7M-27.0%
REPLReplimune Group, Inc.$1.1M-25.7%
ALBOAlbireo Pharma, Inc.$-2.9M-24.9%
← Torna agli Hedge Fund